ReviewNature reviews. Cardiology2020
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.
Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 435 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
435 citing papers in PubMed, 2 syntheses or guidelines pooled it, 688 citations in OpenAlex.
- Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials.Systematic reviews · 2026Pooled it
- Proton Radiation Therapy: A Systematic Review of Treatment-Related Side Effects and Toxicities.International journal of molecular sciences · 2024Pooled it
- Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers.Clinical pharmacology in drug development · 2026Trial
- Anthracycline-induced cardiotoxicity associated with myocardial energy metabolism: mechanisms revealed through an integration ofFrontiers in cardiovascular medicine · 2025Trial
- Surviving cancer, managing the heart: Awareness of potential cardiovascular toxicity and barriers to cardiovascular self-management among women with breast cancer: A qualitative descriptive study.Asia-Pacific journal of oncology nursing · 2026Article
- Effectiveness of self-management interventions in reducing cancer treatment-related cardiotoxicity in breast cancer survivors: A systematic review.Asia-Pacific journal of oncology nursing · 2026Review
- Gaps in Onco-Cardiology Practice and Educational Needs for the Next Generation of Pharmacists in Japan.Circulation reports · 2026Article
- Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies.Journal of thrombosis and thrombolysis · 2026Review
- Review of in vitro approaches for assessing the toxicity of chemical stressors across diverse physiological systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- Mechanistic insights into the mitigating role of dapagliflozin against radiation-triggered myocardial apoptosis: gating to AMPK-regulated autophagic machinery.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Delayed total-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Multidimensional perspectives on cancer therapy-induced cardiotoxicity: Characteristics, mechanisms, biomarkers, psychological stress effects, and treatment progress.Cancer pathogenesis and therapy · 2026Review
- An Integrated Model of Cardiotoxicity: Interaction of Age, Sex, and Genetic Polymorphisms in Patients with Acute Leukemia.Biomedicines · 2026Article
- Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions.Journal of clinical medicine · 2026Review
- Cardiovascular Toxicity in Cancer Therapy: Potential Mechanisms of Ferroptosis and Treatment Strategies.Cells · 2026Review
- AKT (Ser473) suppression mediates ceritinib cardiotoxicity through autophagic flux impairment and mitochondrial injury.Acta pharmacologica Sinica · 2026Article
- Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.Current oncology (Toronto, Ont.) · 2026Observational
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.Biomedicines · 2026Review
- Right Ventricular Metastasis From Cervical Cancer Treated With Pembrolizumab-Containing Chemotherapy: A Case Report and Literature Review.The American journal of case reports · 2026Review
- Review
375 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Remarkable progress has been made in the development of new therapies for cancer, dramatically changing the landscape of treatment approaches for several malignancies and continuing to increase patient survival. Accordingly, adverse effects of cancer therapies that interfere with the continuation of best-possible care, induce life-threatening risks or lead to long-term morbidity are gaining increasing importance. Cardiovascular toxic effects of cancer therapeutics and radiation therapy are the epitome of such concerns, and proper knowledge, interpretation and management are needed and have to be placed within the context of the overall care of individual patients with cancer. Furthermore, the cardiotoxicity spectrum has broadened to include myocarditis with immune checkpoint inhibitors and cardiac dysfunction in the setting of cytokine release syndrome with chimeric antigen receptor T cell therapy. An increase in the incidence of arrhythmias related to inflammation such as atrial fibrillation can also be expected, in addition to the broadening set of cancer therapeutics that can induce prolongation of the corrected QT interval. Therefore, cardiologists of today have to be familiar not only with the cardiotoxicity associated with traditional cancer therapies, such as anthracycline, trastuzumab or radiation therapy, but even more so with an ever-increasing repertoire of therapeutics. This Review provides this information, summarizing the latest developments at the juncture of cardiology, oncology and haematology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.